A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.

NCT00439426 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Cancer

Interventions

DRUG: Oxaliplatin
DRUG: capecitabine [Xeloda]

Sponsor

Hoffmann-La Roche